Drug Radar
Generated 2026-08-14 09:37 · live off the Tickers sheet
Weekly Teach-In
Your watchlist — threats & owned assets
GZR33 Injection, Insulin Degludec Injection (Tresiba®) (603087.SS) — Type 2 Diabetes Mellitus (T2DM)
- Phase PHASE3, primary endpoint: Change in Hemoglobin A1c (HbA1c) from baseline after 26 weeks of treatment., completion 2026-04-07. (NCT07527078)
- Teach-in text unavailable this run — showing grounded facts only.
ORMD-0801 8 mg, ORMD-0801 16 mg (—) — Type 2 Diabetes Mellitus (T2DM)
- Phase PHASE3, primary endpoint: Change from baseline in A1C at 26 weeks, completion 2027-04-25. (NCT06731075)
- Teach-in text unavailable this run — showing grounded facts only.
Setmelanotide (RHYTHMUSD) — Turner Syndrome
- Phase PHASE3, primary endpoint: Mean % change in BMI, completion 2027-03-13. (NCT06760546)
- Teach-in text unavailable this run — showing grounded facts only.
Enlicitide (Merck/MSD, MRK) — Hypercholesterolaemia (high LDL — "bad" — cholesterol in the blood)
- What it is: An oral pill designed to lower LDL-C (low-density lipoprotein cholesterol — the "bad" cholesterol linked to heart attack risk) taken alongside a standard statin (a cholesterol-lowering drug already widely prescribed), representing the most direct competitive threat to injectable cholesterol medicines if it works as a daily tablet.
- Who it moves: This is a material threat to AZN (AstraZeneca), specifically to lecanemab — wait, more precisely to AZN's baxdrostat pipeline and, most directly, to the revenue of Leqvio — actually, AZN's key cholesterol franchise is Leqvio (inclisiran — a twice-yearly injectable cholesterol-lowering medicine, partnered with Novartis but with AZN holding co-promotion rights in some markets); however, Leqvio's commercial home is primarily Novartis (NVS). For AZN directly, the more relevant overlap is with Farxiga (dapagliflozin — a pill for heart failure and kidney disease) only tangentially. Re-assessing: AZN does not own a leading PCSK9-class cholesterol injectable franchise in a way that makes enlicitide a *material* revenue threat to AZN specifically.
SKIP: Enlicitide competes primarily in the PCSK9-inhibitor cholesterol space, which is not a material AZN revenue driver — AZN's cholesterol franchise (Crestor/rosuvastatin is now largely generic and not a meaningful earnings contributor) does not face material risk here.
IBI306, IBI306 (—) — Hypercholesterolaemia
- Phase PHASE3, primary endpoint: Percent change from baseline in LDL-C, completion 2026-09-06. (NCT07473960)
- Teach-in text unavailable this run — showing grounded facts only.
Obicetrapib (NewAmsterdam Pharma / A. Menarini, private) — high cardiovascular risk dyslipidemia (elevated LDL-C, or "bad cholesterol," despite existing treatment)
- What it is: An oral pill designed to lower LDL-C (low-density lipoprotein cholesterol — the "bad" cholesterol linked to heart attack risk) in patients who still have dangerously high cholesterol despite taking maximum doses of existing therapies; it is being tested head-to-head against bempedoic acid (a non-statin oral cholesterol-lowering pill already on the market).
- Who it moves: This is a threat read for AstraZeneca (AZN). AZN markets Farxiga and co-promotes the PCSK9-inhibitor (a powerful injectable cholesterol-lowering drug class) franchise, but more directly, AZN sells Crestor (rosuvastatin — a widely used statin cholesterol pill) generically and has cardiovascular portfolio exposure; critically, a strong obicetrapib win here validates a new oral cholesterol-lowering entrant that competes for the same statin-intolerant, high-risk patient pool that AZN's cardiovascular franchise targets — however, AZN's most material cholesterol-adjacent revenue today is not large enough to make this a primary AZN mover, and the competitive overlap is real but not a top-tier revenue threat.
- Catalyst & timing: The primary endpoint — percentage change in LDL-C from baseline to Day 84 (approximately 12 weeks) versus bempedoic acid — is expected to read out around January 2027, based on the stated primary completion date.
- Size of the prize: No credible consensus peak-sales figure is publicly established for obicetrapib at this stage; the addressable pool is large (millions of statin-intolerant or residual-risk patients in the U.S. and Europe), but commercial sizing will depend heavily on this and other ongoing Phase 3 outcomes.
SKIP: The competitive overlap with AZN is not material enough to AZN's current revenue base to warrant a full teach-in entry; AZN's cholesterol franchise (legacy Crestor generics) is not a top-line driver, and obicetrapib's primary competitive read-through is to bempedoic acid's owner (Esperion Therapeutics) and the broader oral LDL-lowering market rather than to AZN specifically.
---
*Correction to format above — given the materiality assessment, the proper response is:*
SKIP: Obicetrapib's head-to-head versus bempedoic acid (a non-statin cholesterol pill) is most directly a threat to Esperion Therapeutics, not AZN; AZN's cholesterol-related revenue is not a material driver of the stock, so this trial does not create a meaningful AZN exposure.
Orforglipron, Dulaglutide (LLY) — Type 2 Diabetes
- Phase PHASE3, primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c), completion 2030-03. (NCT07668336)
- Teach-in text unavailable this run — showing grounded facts only.
Tirzepatide & Retatrutide (Eli Lilly, LLY) — MASLD/NASH liver-outcomes trial
- What it is: Two of Lilly's injectable weight-loss and metabolic medicines being tested to see whether they can prevent serious liver deterioration — such as cirrhosis (permanent scarring) or liver failure — in patients with MASLD (metabolic dysfunction-associated steatotic liver disease, formerly called NASH or non-alcoholic fatty liver disease, a condition where excess fat damages the liver).
- Who it moves: This is squarely an LLY-owned story. Tirzepatide (Mounjaro/Zepbound — Lilly's already-approved diabetes and obesity injection) is the commercial anchor, and a positive outcomes result here would expand its label into a major new chronic-disease indication; retatrutide (Lilly's next-generation metabolic candidate still in development) is being tested alongside it, giving Lilly a potential two-asset franchise in liver disease. A win validates MASLD as a durable new revenue pillar layered on top of the existing obesity/diabetes business; a miss or safety signal would remove a widely anticipated growth avenue and pressure the long-term earnings trajectory.
- Catalyst & timing: The primary completion date is August 2030, meaning top-line MALO (major adverse liver outcomes — a composite of hard clinical events like cirrhosis progression, liver transplant, or liver-related death) results are unlikely before late 2030 at the earliest, with a roughly 224-week (approximately 4.5-year) treatment period for enrolled participants; no interim readout dates are disclosed in the trial record.
- Size of the prize: The addressable population is large — an estimated 15–20 million Americans have advanced or high-risk MASLD, and global prevalence is substantially higher; credible analyst estimates for the MASLD drug market broadly range from $10–20 billion in peak annual sales across the class, with Lilly potentially capturing a leading share given tirzepatide's existing commercial infrastructure; no Lilly-specific peak-sales figure has been formally guided, but this indication is widely treated by the buy side as one of the largest remaining growth options for the franchise beyond obesity and diabetes.
Eloralintide (LLY) — Obstructive Sleep Apnea
- Phase PHASE3, primary endpoint: Percent Change from Baseline in Body Weight, completion 2028-03. (NCT07369011)
- Teach-in text unavailable this run — showing grounded facts only.
Mivelsiran (ALNY) — Alzheimer Disease
- Phase PHASE2, primary endpoint: Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs), completion 2030-05-18. (NCT07636811)
- Teach-in text unavailable this run — showing grounded facts only.
Resmetirom (MDGL) — MASH
- Phase PHASE2, primary endpoint: Percent change from baseline in liver fat content (LFC) as assessed by MRI-PDFF at Week 28, completion 2028-08. (NCT07335601)
- Teach-in text unavailable this run — showing grounded facts only.
Also notable — category-defining drugs elsewhere
Efimosfermin alfa (GSK.SW) — MASH
- Phase PHASE3, primary endpoint: Part A: Proportion of participants achieving improvement in liver fibrosis by >=1 stage and no worsening of MASH, completion 2030-10-16. (NCT07704892)
- Teach-in text unavailable this run — showing grounded facts only.
Balcinrenone/Dapagliflozin (AstraZeneca, AZN) — Chronic Kidney Disease (Stage 3b/4)
- What it is: A once-daily oral pill combining two kidney-protecting agents into a single tablet for patients with moderately-to-severely reduced kidney function — CKD (chronic kidney disease — a progressive loss of kidney filtering capacity) Stages 3b and 4 represent eGFR (estimated glomerular filtration rate — a measure of how well kidneys filter waste) of 15–45, a population historically excluded from most trials and left with few options beyond standard of care.
- Who it moves: This is squarely an AstraZeneca (AZN) story. Dapagliflozin (Farxiga — AZ's flagship kidney/heart pill, already approved for CKD) is one of AZ's largest revenue drivers, generating roughly $3B+ annually. Balcinrenone (an investigational add-on agent targeting excess aldosterone activity — a hormone that accelerates kidney damage) is AZ's proprietary compound; a positive BalanceD-CKD readout would extend Farxiga's commercial life, open a harder-to-treat patient segment currently underserved, and create a new fixed-dose combination franchise that competitors cannot easily replicate given AZ's ownership of both components.
- Catalyst & timing: Primary completion is July 2030, with the composite endpoint (cardiovascular death, kidney failure, sustained ≥50% eGFR decline, and heart failure events) requiring 2,800 patients. The trial is not yet recruiting, so meaningful interim data or enrollment updates are unlikely before 2026–2027 at earliest; the key data event is the primary readout around mid-2030.
- Size of the prize: Ballpark peak sales for a successful fixed-dose combination in this indication could reach $2B–$3B+ incrementally on top of existing Farxiga revenue — the CKD Stage 3b/4 population numbers in the tens of millions globally, is poorly served, and carries high rates of cardiovascular and kidney failure events that payers will pay to prevent. The Street is likely under-modeling this asset given the trial is pre-recruitment and the combination label does not yet exist; a successful outcome would represent a material, durable revenue extension for AZN's renal franchise into the 2030s.
Elecoglipron (AZNCF) — Chronic Kidney Disease
- Phase PHASE3, primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c), completion 2028-07-13. (NCT07662135)
- Teach-in text unavailable this run — showing grounded facts only.
baxdrostat 2mg (AZNCF) — Hypertension
- Phase PHASE3, primary endpoint: Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12, completion 2028-02-09. (NCT07686120)
- Teach-in text unavailable this run — showing grounded facts only.
NNC0487-0111 (NONOF) — Obstructive Sleep Apnea
- Phase PHASE3, primary endpoint: Relative change in body weight, completion 2028-06-26. (NCT07571109)
- Teach-in text unavailable this run — showing grounded facts only.
Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2 (AZNCF) — COPD
- Phase PHASE3, primary endpoint: Adverse events, completion 2028-12-29. (NCT07566195)
- Teach-in text unavailable this run — showing grounded facts only.
Zasocitinib (TKPHF) — Psoriasis
- Phase PHASE3, primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), completion 2029-12-18. (NCT07286058)
- Teach-in text unavailable this run — showing grounded facts only.
Benralizumab (AZNCF) — Asthma
- Phase PHASE3, primary endpoint: Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab, completion 2029-12-28. (NCT07444567)
- Teach-in text unavailable this run — showing grounded facts only.
JNJ-78934804 (Johnson & Johnson, JNJ) — Moderately to Severely Active Ulcerative Colitis
- What it is: A next-generation oral pill for UC (ulcerative colitis — a chronic inflammatory bowel disease causing ulcers and bleeding in the large intestine) being tested head-to-head against guselkumab (an existing J&J injectable biologic already approved for psoriasis and being developed for UC).
- Who it moves: J&J (JNJ) is the direct owner; the broader read-through is to the IBD (inflammatory bowel disease) franchise, where AbbVie (ABBV) — whose Skyrizi (risankizumab, an injectable biologic for UC and Crohn's disease) and Rinvoq (upadacitinib, an oral JAK inhibitor for UC) together generate well over $10 billion annually — faces the most meaningful competitive pressure if an oral J&J option proves superior or equivalent to injectables; Pfizer (PFE) with Xeljanz (tofacitinib, an oral UC therapy) and Bristol-Myers Squibb (BMY) with Zeposia (ozanimod, an oral UC pill) also have exposure.
- Catalyst & timing: The primary endpoint — percentage of patients in clinical remission (no active disease symptoms) at Week 48 — reads out with primary completion targeted for August 2028; that is the key data event to track.
- Size of the prize: The UC biologic and advanced oral therapy market is broadly estimated at a ballpark peak opportunity of ~$8–10 billion globally, with roughly 1–1.5 million moderate-to-severe UC patients in the U.S. alone eligible for advanced therapy; if JNJ-78934804 delivers an oral option that matches or beats injectable biologics on remission, it could reshape prescribing patterns across the entire IBD category.
Anifrolumab (AZNCF) — Systemic Lupus Erythematosus
- Phase PHASE3, primary endpoint: The proportion of patients who achieve DORIS remission at week 52, completion 2028-08-25. (NCT07751848)
- Teach-in text unavailable this run — showing grounded facts only.
JNJ-78934804, Guselkumab (—) — Crohn Disease
- Phase PHASE3, primary endpoint: Co-Primary: Percentage of Participants with Clinical Remission at Week 48, completion 2028-06-12. (NCT07577843)
- Teach-in text unavailable this run — showing grounded facts only.
Saruparib, Enzalutamide, Darolutamide, Abiraterone (AZNCF) — Prostate Cancer
- Phase PHASE3, primary endpoint: Radiographic progression-free survival (rPFS), completion 2031-06-17. (NCT07711002)
- Teach-in text unavailable this run — showing grounded facts only.
QVM149, Salmeterol Xinafoate / Fluticasone Propionate (NVSEF) — Asthma
- Phase PHASE3, primary endpoint: Change from Baseline in Trough FEV1, completion 2028-12-30. (NCT05776927)
- Teach-in text unavailable this run — showing grounded facts only.
Drug: Atrasentan (NVSEF) — Chronic Kidney Disease
- Phase PHASE3, primary endpoint: Change From Baseline in Proteinuria at Week 36, completion 2031-09-15. (NCT07498335)
- Teach-in text unavailable this run — showing grounded facts only.
None (AZNCF) — Systemic Lupus Erythematosus
- Phase , primary endpoint: n/a, completion None. (NCT07430306)
- Teach-in text unavailable this run — showing grounded facts only.
None (NVSEF) — Atrial Fibrillation
- Phase , primary endpoint: n/a, completion None. (NCT07739888)
- Teach-in text unavailable this run — showing grounded facts only.
None (—) — Schizophrenia
- Phase , primary endpoint: n/a, completion None. (NCT07424404)
- Teach-in text unavailable this run — showing grounded facts only.
None (NONOF) — Obesity
- Phase , primary endpoint: n/a, completion None. (NCT07668401)
- Teach-in text unavailable this run — showing grounded facts only.
None (—) — Ulcerative Colitis
- Phase , primary endpoint: n/a, completion None. (NCT07158242)
- Teach-in text unavailable this run — showing grounded facts only.
None (NONOF) — Obstructive Sleep Apnea
- Phase , primary endpoint: n/a, completion None. (NCT07571005)
- Teach-in text unavailable this run — showing grounded facts only.
Competitive radar — changes vs. last run
New competitor trials & signal upgrades since 2026-08-13.
AMGN Amgen Inc.
- RESULTSPH3 upgrade from PH3 · Thyroid Eye Disease · Viridian Therapeutics, Inc. (VRDN) · readout 2024-11-04 · NCT06021054
- RESULTSPH3 upgrade from PH3 · Thyroid Eye Disease · Viridian Therapeutics, Inc. (VRDN) · readout 2025-05-01 · NCT06384547
- RESULTS Thyroid Eye Disease · Immunovant Sciences GmbH (—) · readout 2025-07-25 · NCT05907668
ALNY · OWNED Alnylam Pharmaceuticals, Inc.
- NEW Hypertension · Tectonic Operating Company, Inc. (—) · readout 2027-11-21 · NCT07473700
AZN · OWNED AstraZeneca PLC
- NEW Systemic Lupus Erythematosus · Curocell Inc. (—) · readout 2030-06 · NCT07364396
BBIO · OWNED BridgeBio Pharma, Inc.
- NEW Polyneuropathies · argenx (ARGNF) · readout 2028-07-28 · NCT07760818
MDGL · OWNED Madrigal Pharmaceuticals, Inc.
- RESULTS MASH · 89bio, Inc. (ETNB) · readout 2023-02-14 · NCT04929483
Weekly — game-changers & blockbusters
Game-changer funnel
| Indication | Sponsor | Ticker | WL | Results | Readout |
|---|---|---|---|---|---|
| NASH | Eli Lilly and Company | LLY | ✓ | 2030-08 | |
| Obstructive Sleep Apnea | Eli Lilly and Company | LLY | ✓ | 2028-03 | |
| Alzheimer Disease | JYAMS PET Research & Development Limited | — | 2027-04-30 | ||
| Parkinson Disease | Hangzhou PhecdaMed Co., Ltd. | — | 2028-01-15 | ||
| Asthma | Novartis Pharmaceuticals | NVSEF | 2028-12-30 | ||
| Multiple Sclerosis | Oculis | OCS | 2027-12 | ||
| Rheumatoid Arthritis | Vor Biopharma | VOR | 2028-12 | ||
| Colorectal Cancer | Exelixis | EXEL | 2030-04-05 | ||
| MASH | GlaxoSmithKline | GSK.SW | 2030-10-16 | ||
| MASH | GlaxoSmithKline | GSK.SW | 2033-07-27 | ||
| Chronic Kidney Disease | AstraZeneca | AZNCF | 2028-07-13 | ||
| Obstructive Sleep Apnea | Novo Nordisk A/S | NONOF | 2028-06-26 | ||
| Atopic Dermatitis | Nektar Therapeutics | NKTR | 2028-05 | ||
| Colorectal Cancer | Genmab | GNMSF | 2029-07 | ||
| Type 2 Diabetes | Ascletis Pharma (China) Co., Limited | — | 2028-07 | ||
| Major Depressive Disorder | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 002773.SZ | 2027-12 | ||
| Major Depressive Disorder | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 002773.SZ | 2027-12 | ||
| Schizophrenia | Bostal Drug Delivery Co., Ltd | — | 2027-08 | ||
| Psoriasis | Takeda | TKPHF | 2029-12-18 | ||
| Ulcerative Colitis | Janssen Research & Development, LLC | — | 2028-08-11 |
Blockbuster candidates
| Indication | Ticker | WL | Mkt Cap $B | Phase | Sponsor |
|---|---|---|---|---|---|
| MASH | MDGL | ✓ | 11.7 | PHASE2 | Madrigal Pharmaceuticals, Inc. |
| Alzheimer Disease | ALNY | ✓ | 30.4 | PHASE2 | Alnylam Pharmaceuticals |
| Type 2 Diabetes | LLY | ✓ | 1139.4 | PHASE3 | Eli Lilly and Company |
| NASH | LLY | ✓ | 1139.4 | PHASE3 | Eli Lilly and Company |
| COPD | LLY | ✓ | 1139.4 | PHASE2 | Eli Lilly and Company |
| Obstructive Sleep Apnea | LLY | ✓ | 1139.4 | PHASE3 | Eli Lilly and Company |
| Ulcerative Colitis | LLY | ✓ | 1139.4 | PHASE2 | Eli Lilly and Company |
| Crohn Disease | LLY | ✓ | 1139.4 | PHASE2 | Eli Lilly and Company |
| Parkinson Disease | HLUYY | — | PHASE2 | H. Lundbeck A/S | |
| Osteoarthritis | LGMK | 0.0 | PHASE1/PHASE2 | ICM Co. Ltd. | |
| Multiple Sclerosis | RVLPQ | 0.0 | PHASE3 | RVL Pharmaceuticals, Inc. | |
| Lung Cancer | ORGS | 0.0 | PHASE1/PHASE2 | Rgene Corporation | |
| Breast Cancer | SURG | 0.0 | PHASE3 | SURGE Therapeutics | |
| Obesity | LUMO | 0.0 | PHASE2 | Lumos Pharma | |
| Obstructive Sleep Apnea | IXHL | 0.0 | PHASE2 | Incannex Healthcare Ltd | |
| MASH | ALGS | 0.0 | PHASE2 | Aligos Therapeutics | |
| Rheumatoid Arthritis | XBIT | 0.1 | PHASE2 | XBiotech, Inc. | |
| Breast Cancer | TELO | 0.1 | PHASE1/PHASE2 | Telomir Pharmaceuticals, Inc. | |
| Alzheimer Disease | ANVS | 0.1 | PHASE2/PHASE3 | Annovis Bio Inc. | |
| Lung Cancer | 0R4W.L | 0.1 | PHASE2/PHASE3 | Multitude Therapeutics Inc. |
Track 1 — full competitive map
AZN · OWNED — AstraZeneca PLC (76 trials · 15 readouts · 58 new)
Franchises: Type 2 Diabetes Mellitus, Hypercholesterolaemia, Systemic Lupus Erythematosus, Metastatic Prostate Cancer
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Hypercholesterolaemia | Merck Sharp & Dohme LLC | — | PHASE3 | 2026-08-12 | NCT07216482 |
| NEWREADOUTPH3 | Hypercholesterolaemia | Innovent Biologics (Suzhou) Co. Ltd. | — | PHASE3 | 2026-09-06 | NCT07473960 |
| NEWREADOUTPH3 | Hypercholesterolaemia | A. Menarini International Licensing S.A. | — | PHASE3 | 2027-01 | NCT07614958 |
| NEWREADOUT | Hypercholesterolaemia | Eddingpharm (Zhuhai) Co., Ltd. | — | PHASE2 | 2026-10-04 | NCT07489209 |
| NEWREADOUT | Hypercholesterolaemia | Regeneron Pharmaceuticals | REGN | PHASE2 | 2026-12-29 | NCT07477704 |
| NEWREADOUT | Metastatic Prostate Cancer | Second Life Therapeutics | — | PHASE1/PHASE2 | 2027-01-01 | NCT07341737 |
| NEWREADOUT | Systemic Lupus Erythematosus | Beijing Biotech | — | PHASE1/PHASE2 | 2027-03-14 | NCT07523542 |
| NEWREADOUT | Systemic Lupus Erythematosus | Sinocelltech Ltd. | 688520.SS | PHASE1/PHASE2 | 2027-04 | NCT07538154 |
| NEWREADOUT | Metastatic Prostate Cancer | Beijing Biotech | — | PHASE1/PHASE2 | 2027-04-14 | NCT07523529 |
| NEWREADOUT | Hypercholesterolaemia | Novartis Pharmaceuticals | NVSEF | PHASE2 | 2027-04-28 | NCT07610278 |
| READOUTPH3 | Hypercholesterolaemia | Addpharma Inc. | — | PHASE3 | 2025-12 | NCT06747936 |
| READOUTPH3 | Hypercholesterolaemia | Visirna Therapeutics HK Limited | — | PHASE3 | 2025-12-31 | NCT06712771 |
| READOUTPH3 | Type 2 Diabetes Mellitus | Eurofarma Laboratorios S.A. | — | PHASE3 | 2027-04-30 | NCT06560333 |
| READOUT | Hypercholesterolaemia | Beijing Suncadia Pharmaceuticals Co., Ltd | — | PHASE2 | 2025-12 | NCT07133815 |
| READOUT | Hypercholesterolaemia | Qilu Pharmaceutical Co., Ltd. | — | PHASE2 | 2026-06 | NCT06750341 |
RVMD — Revolution Medicines, Inc. (52 trials · 7 readouts · 46 new)
Franchises: PDAC, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | PDAC | Ranok Therapeutics (Hangzhou) Co., Ltd. | — | PHASE2 | 2026-11-30 | NCT07303465 |
| NEWREADOUT | PDAC | Shenyang Sunshine Pharmaceutical Co., LTD. | — | PHASE2 | 2026-12 | NCT07233850 |
| NEWREADOUT | Pancreatic Cancer | Second Life Therapeutics | — | PHASE1/PHASE2 | 2027-01-01 | NCT07341737 |
| NEWREADOUT | PDAC | Beijing Biotech | — | PHASE1/PHASE2 | 2027-02-14 | NCT07480928 |
| NEWREADOUT | PDAC | Beijing Biotech | — | PHASE1/PHASE2 | 2027-04-14 | NCT07627711 |
| NEWREADOUT | Pancreatic Cancer | Rgene Corporation | ORGS | PHASE2 | 2027-04-30 | NCT03301805 |
| READOUT | PDAC | Guangzhou JOYO Pharma Co., Ltd | — | PHASE2 | 2026-03-30 | NCT06895031 |
| NEWPH3 | PDAC | SOFIE | — | PHASE3 | 2027-12-31 | NCT07217717 |
| NEWPH3 | PDAC - Pancreatic Ductal Adenocarcinoma | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | — | PHASE3 | 2028-05 | NCT07165951 |
| NEWPH3 | PDAC | Immuneering Corporation | IMRX | PHASE3 | 2028-06 | NCT07562152 |
| NEWPH3 | PDAC - Pancreatic Ductal Adenocarcinoma | Chipscreen Biosciences, Ltd. | — | PHASE3 | 2028-06-30 | NCT07445295 |
| NEWPH3 | PDAC | Incyte Corporation | INCY | PHASE3 | 2028-09-15 | NCT07522073 |
| NEWPH3 | PDAC | Bristol-Myers Squibb | BMY | PHASE2/PHASE3 | 2029-05-03 | NCT07076121 |
| NEWPH3 | PDAC | Astellas Pharma Global Development, Inc. | — | PHASE3 | 2029-08-31 | NCT07409272 |
| NEWPH3 | PDAC | AbbVie | ABBV | PHASE2/PHASE3 | 2031-06 | NCT07490301 |
MRK — Merck & Co., Inc. (50 trials · 10 readouts · 38 new)
Franchises: Malignant Neoplasm, Non-small Cell Lung Cancer, Bladder Cancer, Diabetic Retinopathy
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Diabetic Retinopathy | Ocular Therapeutix, Inc. | OCUL | PHASE3 | 2027-03 | NCT07235085 |
| NEWREADOUT | Diabetic Retinopathy | Sam Chun Dang Pharm. Co. Ltd. | 000250.KQ | PHASE2 | 2026-05-27 | NCT07501052 |
| NEWREADOUT | Diabetic Retinopathy | Annexin Pharmaceuticals AB | ANNX.ST | PHASE2 | 2026-07 | NCT07259928 |
| NEWREADOUT | Diabetic Retinopathy | Qlaris Bio, Inc. | — | PHASE2 | 2026-09 | NCT07354477 |
| NEWREADOUT | Non-small Cell Lung Cancer | Second Life Therapeutics | — | PHASE1/PHASE2 | 2027-01-01 | NCT07341737 |
| READOUTPH3 | Diabetic Retinopathy | Kodiak Sciences Inc | KOD | PHASE3 | 2026-02-13 | NCT06270836 |
| READOUTPH3 | Diabetic Retinopathy | Beletalent (Zhuhai) Pharmaceutical Co., Ltd | — | PHASE3 | 2026-08-30 | NCT06817265 |
| READOUT | Diabetic Retinopathy | EyeBiotech Ltd. | — | PHASE1/PHASE2 | 2026-03-25 | NCT06664502 |
| READOUT | Diabetic Retinopathy | Vantage Biosciences Ltd | — | PHASE2 | 2027-03 | NCT06770933 |
| READOUT | Diabetic Retinopathy | Boehringer Ingelheim | — | PHASE2 | 2027-03-05 | NCT06321302 |
| RESULTS | Diabetic Retinopathy | Aviceda Therapeutics, Inc. | — | PHASE2 | 2024-04-05 | NCT06181227 |
| NEWPH3 | Bladder Cancer | Relmada Therapeutics, Inc. | RLMD | PHASE3 | 2027-06-30 | NCT07342517 |
| NEWPH3 | Bladder Cancer | Protara Therapeutics | TARA | PHASE3 | 2028-04 | NCT07480356 |
| NEWPH3 | Diabetic Retinopathy | AbbVie | ABBV | PHASE2/PHASE3 | 2028-06 | NCT07592273 |
| NEWPH3 | Bladder Cancer | Relmada Therapeutics, Inc. | RLMD | PHASE3 | 2029-09 | NCT07464145 |
JNJ — Johnson & Johnson (42 trials · 8 readouts · 34 new)
Franchises: Carcinoma, Non-Small-Cell Lung, Orthodontic Pain, Visual Acuity, Dry Eye
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Visual Acuity | Ocuphire Pharma, Inc. | OCUP | PHASE3 | 2026-06 | NCT07140783 |
| NEWREADOUTPH3 | Dry Eye | AbbVie | ABBV | PHASE3 | 2026-08 | NCT07284381 |
| NEWREADOUTPH3 | Dry Eye | Oculis | OCS | PHASE2/PHASE3 | 2026-12 | NCT07548632 |
| NEWREADOUTPH3 | Dry Eye | Bausch & Lomb Incorporated | — | PHASE3 | 2027-04 | NCT07111013 |
| NEWREADOUT | Dry Eye | BRIM Biotechnology Inc. | 6885.TW | PHASE2 | 2026-11 | NCT07078955 |
| NEWREADOUT | Carcinoma, Non-Small-Cell Lung | Second Life Therapeutics | — | PHASE1/PHASE2 | 2027-01-01 | NCT07341737 |
| NEWREADOUT | Dry Eye | Dompé Farmaceutici S.p.A | — | PHASE2 | 2027-01-24 | NCT07503886 |
| READOUT | Visual Acuity | Novartis Pharmaceuticals | NVSEF | PHASE2 | 2026-10-01 | NCT05230537 |
| NEWPH3 | Visual Acuity | Aurion Biotech | — | PHASE3 | 2027-06 | NCT07368959 |
| NEWPH3 | Visual Acuity | Oculis | OCS | PHASE3 | 2027-12 | NCT07623668 |
| NEWPH3 | Dry Eye | Vor Biopharma | VOR | PHASE3 | 2028-12 | NCT07404865 |
| NEWPH3 | Dry Eye | Ocumension Therapeutics (Suzhou) Co., Ltd | — | PHASE3 | 2029-01 | NCT07740564 |
| NEWPH3 | Dry Eye | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2029-08-13 | NCT07621809 |
| NEWPH3 | Carcinoma, Non-Small-Cell Lung | Sichuan Baili Pharmaceutical Co., Ltd. | — | PHASE2/PHASE3 | 2029-12 | NCT07739186 |
| NEWPH3 | Carcinoma, Non-Small-Cell Lung | Sichuan Baili Pharmaceutical Co., Ltd. | — | PHASE2/PHASE3 | 2029-12 | NCT07739199 |
MDGL · OWNED — Madrigal Pharmaceuticals, Inc. (48 trials · 19 readouts · 21 new)
Franchises: MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH, NASH, NASH - Nonalcoholic Steatohepatitis
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | MASH | Hinova Pharmaceuticals Inc. | — | PHASE2 | 2026-08-13 | NCT07308548 |
| NEWREADOUT | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Rivus Pharmaceuticals, Inc. | — | PHASE2 | 2027-02 | NCT07491458 |
| NEWREADOUT | NASH | AB Biotics, SA | — | PHASE2 | 2027-02-01 | NCT07193927 |
| NEWREADOUT | NASH | Hudson Biotech | — | PHASE2 | 2027-02-14 | NCT07481734 |
| NEWREADOUT | NASH | Sinew Pharma Inc. | 6634.TWO | PHASE2 | 2027-04-30 | NCT03468556 |
| READOUTPH3 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Akero Therapeutics, Inc | AKRO | PHASE3 | 2026-03-03 | NCT06161571 |
| READOUTPH3 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Sagimet Biosciences Inc. | SGMT | PHASE3 | 2026-06 | NCT06692283 |
| READOUTPH3 | NASH | Innovent Biologics (Suzhou) Co. Ltd. | — | PHASE3 | 2026-12-31 | NCT06884293 |
| READOUT | NASH - Nonalcoholic Steatohepatitis | Altimmune, Inc. | ALT | PHASE2 | 2025-11-25 | NCT05989711 |
| READOUT | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Enyo Pharma | 6517.T | PHASE2 | 2025-12-22 | NCT06939816 |
| READOUT | NASH - Nonalcoholic Steatohepatitis | Merck Sharp & Dohme LLC | — | PHASE2 | 2025-12-29 | NCT05877547 |
| READOUT | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Boehringer Ingelheim | — | PHASE2 | 2026-01-13 | NCT06675929 |
| READOUT | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Innovent Biologics (Suzhou) Co. Ltd. | — | PHASE2 | 2026-04-30 | NCT06937749 |
| READOUT | NASH - Nonalcoholic Steatohepatitis | Guangdong Raynovent Biotech Co., Ltd | — | PHASE2 | 2026-06-16 | NCT05692492 |
| READOUT | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Zhejiang Doer Biologics Co., Ltd. | — | PHASE2 | 2026-06-18 | NCT07024212 |
TEVA · OWNED — Teva Pharmaceutical Industries Limited (71 trials · 12 readouts · 27 new)
Franchises: Growth Hormone-Deficiency, Amyotrophic Lateral Sclerosis, Relapsing Remitting Multiple Sclerosis
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Amyotrophic Lateral Sclerosis | Coya Therapeutics | COYA | PHASE2/PHASE3 | 2027-01 | NCT07161999 |
| NEWREADOUT | Growth Hormone-Deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | — | PHASE2 | 2026-04-15 | NCT07259564 |
| NEWREADOUT | Amyotrophic Lateral Sclerosis | PLL TX AUSTRALIA PTY LTD | — | PHASE1/PHASE2 | 2026-12-15 | NCT06513546 |
| NEWREADOUT | Amyotrophic Lateral Sclerosis | Inflammasome Therapeutics | — | PHASE1/PHASE2 | 2027-01 | NCT07396818 |
| NEWREADOUT | Amyotrophic Lateral Sclerosis | PhenoNet, Inc. | — | PHASE2 | 2027-03 | NCT07142291 |
| NEWREADOUT | Amyotrophic Lateral Sclerosis | Nura Bio | — | PHASE1/PHASE2 | 2027-04 | NCT07369076 |
| READOUTPH3 | Relapsing Remitting Multiple Sclerosis | Celltrion | 068270.KS | PHASE3 | 2027-02 | NCT05906992 |
| READOUTPH3 | Relapsing Remitting Multiple Sclerosis | Amgen | AMGUSD | PHASE3 | 2027-04-19 | NCT06700343 |
| RESULTSPH3 | Growth Hormone-Deficiency | Novo Nordisk A/S | NONOF | PHASE3 | 2016-01-04 | NCT02382939 |
| RESULTSPH3 | Growth Hormone-Deficiency | OPKO Health, Inc. | OPK | PHASE3 | 2016-08 | NCT01909479 |
| RESULTSPH3 | Growth Hormone-Deficiency | AEterna Zentaris | AEZS | PHASE3 | 2016-11-29 | NCT02558829 |
| RESULTSPH3 | Growth Hormone-Deficiency | Novo Nordisk A/S | NONOF | PHASE3 | 2017-04-21 | NCT02229851 |
| RESULTSPH3 | Growth Hormone-Deficiency | Versartis Inc. | VSAR | PHASE3 | 2017-08-23 | NCT02339090 |
| RESULTSPH3 | Growth Hormone-Deficiency | Novo Nordisk A/S | NONOF | PHASE3 | 2018-10-04 | NCT03075644 |
| RESULTSPH3 | Growth Hormone-Deficiency | Ascendis Pharma Endocrinology Division A/S | — | PHASE3 | 2019-01-17 | NCT02781727 |
INSM · OWNED — Insmed Incorporated (39 trials · 10 readouts · 24 new)
Franchises: Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Mycobacterium Infections, Nontuberculous
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | Pulmonary Hypertension | Salubris Biotherapeutics Inc | — | PHASE2 | 2026-04-16 | NCT07221513 |
| NEWREADOUT | Cystic Fibrosis | Sionna Therapeutics Inc. | SION | PHASE2 | 2026-07 | NCT07108153 |
| NEWREADOUT | Pulmonary Hypertension | Pulmovant, Inc. | — | PHASE2 | 2026-12 | NCT07333183 |
| NEWREADOUT | Pulmonary Hypertension | AllRock Bio, Inc. | — | PHASE2 | 2027-03 | NCT07175038 |
| READOUTPH3 | Cystic Fibrosis | Haisco Pharmaceutical Group Co., Ltd. | 002653.SZ | PHASE3 | 2026-11-28 | NCT06660992 |
| RESULTSPH3 | Mycobacterium Infections, Nontuberculous | AN2 Therapeutics, Inc | ANTX | PHASE2/PHASE3 | 2024-12-18 | NCT05327803 |
| READOUT | Cystic Fibrosis | Boehringer Ingelheim | — | PHASE1/PHASE2 | 2026-02-03 | NCT06515002 |
| READOUT | Cystic Fibrosis | BiomX Ltd | PHGE | PHASE2 | 2026-03 | NCT06998043 |
| READOUT | Cystic Fibrosis | Respirion Pharmaceuticals Pty Ltd | — | PHASE1/PHASE2 | 2026-04-15 | NCT06016088 |
| READOUT | Cystic Fibrosis | Spirovant Sciences, Inc. | — | PHASE1/PHASE2 | 2026-12-31 | NCT06526923 |
| READOUT | Cystic Fibrosis | S-INFINITY Pharmaceuticals Co., Ltd | — | PHASE2 | 2027-01-08 | NCT06981091 |
| RESULTS | Mycobacterium Infections, Nontuberculous | Savara Inc. | SVRA | PHASE2 | 2019-10-15 | NCT03421743 |
| RESULTS | Mycobacterium Infections, Nontuberculous | Savara Inc. | SVRA | PHASE2 | 2020-10-02 | NCT03597347 |
| RESULTS | Mycobacterium Infections, Nontuberculous | Spero Therapeutics | SPRO | PHASE2 | 2021-01-28 | NCT04553406 |
| RESULTS | Mycobacterium Infections, Nontuberculous | Paratek Pharmaceuticals Inc | PRTK | PHASE2 | 2024-06-17 | NCT04922554 |
TGTX — TG Therapeutics, Inc. (74 trials · 13 readouts · 21 new)
Franchises: Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Small Lymphocytic Lymphoma
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| READOUTPH3 | Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | — | PHASE3 | 2026-01-27 | NCT04586010 |
| READOUTPH3 | Relapsing Multiple Sclerosis | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2026-01-28 | NCT06869785 |
| READOUTPH3 | Relapsing Multiple Sclerosis (RMS) | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2026-03-25 | NCT04926818 |
| READOUTPH3 | Relapsing Multiple Sclerosis (RMS) | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2026-07-23 | NCT05147220 |
| READOUTPH3 | Relapsing Multiple Sclerosis (RMS) | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2026-07-23 | NCT05156281 |
| READOUTPH3 | Relapsing Multiple Sclerosis | Sandoz | SDZNY | PHASE3 | 2026-11 | NCT06847724 |
| READOUTPH3 | Small Lymphocytic Lymphoma | Ascentage Pharma Group Inc. | AAPGV | PHASE3 | 2026-12-31 | NCT06104566 |
| READOUTPH3 | Relapsing Multiple Sclerosis | Celltrion | 068270.KS | PHASE3 | 2027-02 | NCT05906992 |
| READOUTPH3 | Relapsing Multiple Sclerosis | Amgen | AMGUSD | PHASE3 | 2027-04-19 | NCT06700343 |
| READOUTPH3 | Relapsing Multiple Sclerosis | Sanofi | SNYNF | PHASE3 | 2027-05-06 | NCT06141473 |
| RESULTSPH3 | Relapsing Multiple Sclerosis (RMS) | EMD Serono | — | PHASE3 | 2009-01 | NCT00735007 |
| RESULTSPH3 | Relapsing Multiple Sclerosis (RMS) | EMD Serono | — | PHASE3 | 2010-04 | NCT00958009 |
| RESULTSPH3 | Relapsing Multiple Sclerosis (RMS) | EMD Serono | — | PHASE3 | 2010-08 | NCT01036165 |
| RESULTSPH3 | Relapsing Multiple Sclerosis (RMS) | Celgene | CELG | PHASE3 | 2016-12-22 | NCT02294058 |
| RESULTSPH3 | Relapsing Multiple Sclerosis (RMS) | Genentech, Inc. | — | PHASE3 | 2019-05-31 | NCT03606460 |
AMGN — Amgen Inc. (43 trials · 16 readouts · 16 new)
Franchises: Obesity, Overweight, Thyroid Eye Disease, Cardiovascular Disease
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Thyroid Eye Disease | Innovent Biologics (Suzhou) Co. Ltd. | — | PHASE3 | 2026-12-31 | NCT07113262 |
| NEWREADOUTPH3 | Thyroid Eye Disease | Zai Lab (Shanghai) Co., Ltd. | — | PHASE3 | 2027-03-14 | NCT07211776 |
| NEWREADOUTPH3 | Thyroid Eye Disease | Beijing Kanghong Biological Medicine Co., Ltd. | — | PHASE3 | 2027-04 | NCT07720635 |
| NEWREADOUTPH3 | Thyroid Eye Disease | Beijing Kanghong Biological Medicine Co., Ltd. | — | PHASE3 | 2027-05 | NCT07720648 |
| NEWREADOUT | Thyroid Eye Disease | Sanofi | SNYNF | PHASE2 | 2026-08-25 | NCT06984627 |
| READOUTPH3 | Thyroid Eye Disease | argenx | ARGNF | PHASE3 | 2025-12-15 | NCT06307626 |
| READOUTPH3 | Thyroid Eye Disease | argenx | ARGNF | PHASE3 | 2025-12-15 | NCT06307613 |
| READOUTPH3 | Thyroid Eye Disease | Viridian Therapeutics, Inc. | VRDN | PHASE3 | 2026-02-12 | NCT06625411 |
| READOUTPH3 | Thyroid Eye Disease | Viridian Therapeutics, Inc. | VRDN | PHASE3 | 2026-03-04 | NCT06625398 |
| READOUTPH3 | Thyroid Eye Disease | Viridian Therapeutics, Inc. | VRDN | PHASE3 | 2026-04-22 | NCT06812325 |
| READOUTPH3 | Thyroid Eye Disease | Viridian Therapeutics, Inc. | VRDN | PHASE3 | 2026-05-28 | NCT07155668 |
| READOUTPH3 | Thyroid Eye Disease | Sling Therapeutics, Inc. | SLBG | PHASE2/PHASE3 | 2026-06 | NCT06112340 |
| READOUTPH3 | Thyroid Eye Disease | Minghui Pharmaceutical (Hangzhou) Ltd | — | PHASE3 | 2026-07-31 | NCT06989918 |
| RESULTSPH3 | Thyroid Eye Disease | Viridian Therapeutics, Inc. | VRDN | PHASE3 | 2024-11-04 | NCT06021054 |
| RESULTSPH3 | Thyroid Eye Disease | Viridian Therapeutics, Inc. | VRDN | PHASE3 | 2025-05-01 | NCT06384547 |
ALNY · OWNED — Alnylam Pharmaceuticals, Inc. (48 trials · 11 readouts · 19 new)
Franchises: Hypertension, TTR-mediated Amyloidosis, Type 2 Diabetes Mellitus (T2DM), Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Type 2 Diabetes Mellitus (T2DM) | Gan & Lee Pharmaceuticals. | 603087.SS | PHASE3 | 2026-04-07 | NCT07527078 |
| NEWREADOUTPH3 | Type 2 Diabetes Mellitus (T2DM) | Oramed, Ltd. | — | PHASE3 | 2027-04-25 | NCT06731075 |
| NEWREADOUT | Type 2 Diabetes Mellitus (T2DM) | Halia Therapeutics, Inc. | THAT.L | PHASE2 | 2026-01-23 | NCT07172867 |
| NEWREADOUT | Type 2 Diabetes Mellitus (T2DM) | Ascletis Pharma (China) Co., Limited | — | PHASE2 | 2026-08 | NCT07321678 |
| NEWREADOUT | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Neurimmune AG | — | PHASE2 | 2026-10-31 | NCT07213583 |
| NEWREADOUT | Type 2 Diabetes Mellitus (T2DM) | Gan & Lee Pharmaceuticals. | 603087.SS | PHASE2 | 2027-02-11 | NCT07387003 |
| NEWREADOUT | Type 2 Diabetes Mellitus (T2DM) | Fujian Shengdi Pharmaceutical Co., Ltd. | — | PHASE2 | 2027-05 | NCT07599410 |
| READOUTPH3 | TTR-mediated Amyloidosis | Ionis Pharmaceuticals, Inc. | IONS | PHASE3 | 2026-04 | NCT04136171 |
| READOUTPH3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | AstraZeneca | AZNCF | PHASE3 | 2026-05-13 | NCT06194825 |
| READOUTPH3 | TTR-mediated Amyloidosis | Eidos Therapeutics, a BridgeBio company | — | PHASE3 | 2026-09 | NCT04882735 |
| RESULTSPH3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Pfizer | PFE | PHASE3 | 2018-02-07 | NCT01994889 |
| RESULTSPH3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Pfizer | PFE | PHASE3 | 2019-11-20 | NCT00935012 |
| RESULTSPH3 | TTR-mediated Amyloidosis | Ionis Pharmaceuticals, Inc. | IONS | PHASE3 | 2023-04-11 | NCT04136184 |
| RESULTSPH3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Eidos Therapeutics, a BridgeBio company | — | PHASE3 | 2023-05-11 | NCT03860935 |
| RESULTSPH3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Pfizer | PFE | PHASE3 | 2023-10-26 | NCT02791230 |
BBIO · OWNED — BridgeBio Pharma, Inc. (49 trials · 10 readouts · 17 new)
Franchises: Amyloid Cardiomyopathy, Achondroplasia, Amyloid Cardiomyopathy, Transthyretin-Related, Polyneuropathies
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Polyneuropathies | Annexon, Inc. | ANNX | PHASE3 | 2026-12-31 | NCT07020819 |
| NEWREADOUT | Polyneuropathies | BeiGene | BGNE | PHASE2 | 2026-05-12 | NCT07100938 |
| NEWREADOUT | Polyneuropathies | Immunovant Sciences GmbH | — | PHASE2 | 2026-07-16 | NCT07188844 |
| NEWREADOUT | Amyloid Cardiomyopathy | Neurimmune AG | — | PHASE2 | 2026-10-31 | NCT07213583 |
| NEWREADOUT | Polyneuropathies | AllRock Bio, Inc. | — | PHASE2 | 2027-03 | NCT07175038 |
| READOUTPH3 | Amyloid Cardiomyopathy | Lantheus Germany GmbH | — | PHASE3 | 2026-04-21 | NCT05184088 |
| READOUTPH3 | Amyloid Cardiomyopathy | AstraZeneca | AZNCF | PHASE3 | 2026-05-13 | NCT06194825 |
| RESULTSPH3 | Amyloid Cardiomyopathy, Transthyretin-Related | Alnylam Pharmaceuticals | ALNY* | PHASE3 | 2017-03-30 | NCT02319005 |
| RESULTSPH3 | Achondroplasia | BioMarin Pharmaceutical | BMRN | PHASE3 | 2019-10-30 | NCT03197766 |
| RESULTSPH3 | Amyloid Cardiomyopathy, Transthyretin-Related | Alnylam Pharmaceuticals | ALNY* | PHASE3 | 2020-10-06 | NCT03862807 |
| RESULTSPH3 | Amyloid Cardiomyopathy, Transthyretin-Related | Alnylam Pharmaceuticals | ALNY* | PHASE3 | 2020-11-10 | NCT03759379 |
| RESULTSPH3 | Amyloid Cardiomyopathy, Transthyretin-Related | Alnylam Pharmaceuticals | ALNY* | PHASE3 | 2022-06-20 | NCT03997383 |
| RESULTSPH3 | Amyloid Cardiomyopathy | Alexion Pharmaceuticals, Inc. | ALXN | PHASE3 | 2023-11-08 | NCT04622046 |
| RESULTSPH3 | Amyloid Cardiomyopathy, Transthyretin-Related | Alnylam Pharmaceuticals | ALNY* | PHASE3 | 2024-05-08 | NCT04153149 |
| RESULTSPH3 | Achondroplasia | Ascendis Pharma Growth Disorders A/S | — | PHASE2/PHASE3 | 2024-08-09 | NCT05598320 |
GKOS · OWNED — Glaukos Corporation (22 trials · 12 readouts · 12 new)
Franchises: Ocular Hypertension, Keratoconus, Glaucoma, Open Angle Glaucoma
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Ocular Hypertension | Alcon Research | — | PHASE3 | 2026-04-06 | NCT07082816 |
| NEWREADOUTPH3 | Ocular Hypertension | Qlaris Bio, Inc. | — | PHASE2/PHASE3 | 2026-07-22 | NCT07354516 |
| NEWREADOUT | Ocular Hypertension | Bausch & Lomb Incorporated | — | PHASE2 | 2026-05-18 | NCT07168902 |
| NEWREADOUT | Ocular Hypertension | Qlaris Bio, Inc. | — | PHASE2 | 2026-09 | NCT07354477 |
| NEWREADOUT | Keratoconus | TheiaNova Ltd. | — | PHASE1/PHASE2 | 2026-12-31 | NCT07388069 |
| READOUTPH3 | Keratoconus | Epion Therapeutics | HEPA | PHASE3 | 2026-02-13 | NCT06100952 |
| READOUTPH3 | Keratoconus | Epion Therapeutics | HEPA | PHASE3 | 2026-05-27 | NCT06100939 |
| READOUTPH3 | Keratoconus | Price Vision Group | — | PHASE2/PHASE3 | 2026-06-01 | NCT03922542 |
| READOUTPH3 | Open Angle Glaucoma | Santen Pharmaceutical Co., Ltd. | SNPHY | PHASE3 | 2026-08-31 | NCT06666855 |
| READOUT | Ocular Hypertension | Qlaris Bio, Inc. | — | PHASE2 | 2026-02-23 | NCT06030193 |
| READOUT | Open Angle Glaucoma | PolyActiva Pty Ltd | — | PHASE2 | 2026-11-15 | NCT06964191 |
| READOUT | Open Angle Glaucoma | EyeD Pharma | — | PHASE1/PHASE2 | 2027-01 | NCT07036510 |
| RESULTS | Open Angle Glaucoma | Laboratoires Thea | — | PHASE2 | 2024-11-21 | NCT06394973 |
| NEWPH3 | Ocular Hypertension | Huons Co., Ltd. | 243070.KQ | PHASE3 | 2027-11 | NCT07335211 |
| NEWPH3 | Ocular Hypertension | YS Life Science Co., Ltd. | — | PHASE3 | 2027-11-01 | NCT07661329 |
XENE · OWNED — Xenon Pharmaceuticals Inc. (39 trials · 12 readouts · 10 new)
Franchises: Major Depressive Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar Disorder
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | Bipolar I Disorder | Alzamend Neuro, Inc. | ALZN | PHASE1/PHASE2 | 2026-12 | NCT07540338 |
| NEWREADOUT | Bipolar I Disorder | AbbVie | ABBV | PHASE2 | 2027-04 | NCT07220460 |
| READOUTPH3 | Bipolar I Disorder | Intra-Cellular Therapies, Inc. | ITCI | PHASE3 | 2026-02-24 | NCT06462586 |
| READOUTPH3 | Bipolar I Disorder | Intra-Cellular Therapies, Inc. | ITCI | PHASE3 | 2026-05-15 | NCT06462612 |
| READOUTPH3 | Bipolar I Disorder | Alkermes, Inc. | ALKS | PHASE3 | 2026-09 | NCT05303064 |
| READOUTPH3 | Bipolar I Disorder | Bristol-Myers Squibb | BMY | PHASE3 | 2026-11-01 | NCT06951698 |
| READOUTPH3 | Bipolar I Disorder | Bristol-Myers Squibb | BMY | PHASE3 | 2026-11-02 | NCT06951711 |
| READOUTPH3 | Bipolar I Disorder | AbbVie | ABBV | PHASE3 | 2027-03 | NCT04777357 |
| RESULTSPH3 | Bipolar I Disorder | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | — | PHASE3 | 2020-07-31 | NCT03768726 |
| RESULTSPH3 | Bipolar I Disorder | AbbVie | ABBV | PHASE3 | 2022-09-05 | NCT03573297 |
| RESULTSPH3 | Bipolar I Disorder | Vanda Pharmaceuticals | VNDA | PHASE3 | 2022-09-07 | NCT04819776 |
| RESULTSPH3 | Bipolar I Disorder | Intra-Cellular Therapies, Inc. | ITCI | PHASE3 | 2022-11-30 | NCT04285515 |
| RESULTSPH3 | Bipolar I Disorder | Sumitomo Pharma America, Inc. | — | PHASE3 | 2023-10-18 | NCT05169710 |
| RESULTSPH3 | Bipolar I Disorder | Sumitomo Pharma America, Inc. | — | PHASE3 | 2023-11-17 | NCT05227209 |
| READOUT | Bipolar Depression | Autobahn Therapeutics, Inc. | TXLUSD | PHASE2 | 2026-04-22 | NCT06869187 |
NBIX · OWNED — Neurocrine Biosciences, Inc. (34 trials · 1 readouts · 18 new)
Franchises: Schizophrenia, Tardive Dyskinesia, Major Depressive Disorder, Tourette Syndrome
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| RESULTSPH3 | Tardive Dyskinesia | Auspex Pharmaceuticals, Inc. | — | PHASE2/PHASE3 | 2015-05 | NCT02195700 |
| RESULTSPH3 | Tardive Dyskinesia | Auspex Pharmaceuticals, Inc. | — | PHASE3 | 2016-08-19 | NCT02291861 |
| RESULTSPH3 | Tourette Syndrome | Teva Branded Pharmaceutical Products R&D, Inc. | — | PHASE2/PHASE3 | 2019-11-12 | NCT03452943 |
| RESULTSPH3 | Tardive Dyskinesia | Auspex Pharmaceuticals, Inc. | — | PHASE3 | 2019-12-06 | NCT02198794 |
| RESULTSPH3 | Tourette Syndrome | Teva Branded Pharmaceutical Products R&D, Inc. | — | PHASE3 | 2019-12-09 | NCT03571256 |
| RESULTSPH3 | Tourette Syndrome | Teva Branded Pharmaceutical Products R&D, Inc. | — | PHASE3 | 2020-05-15 | NCT03567291 |
| RESULTSPH3 | Tardive Dyskinesia | Tanabe Pharma Corporation | 9644.T | PHASE2/PHASE3 | 2020-09-29 | NCT03176771 |
| RESULTSPH3 | Tourette Syndrome | Emalex Biosciences Inc. | — | PHASE3 | 2025-01-13 | NCT05615220 |
| READOUT | Tourette Syndrome | Noema Pharma AG | — | PHASE2 | 2026-06 | NCT06315751 |
| RESULTS | Tourette Syndrome | Emalex Biosciences Inc. | — | PHASE2 | 2021-09-23 | NCT04007991 |
| RESULTS | Tourette Syndrome | Emalex Biosciences Inc. | — | PHASE2 | 2022-11-11 | NCT04114539 |
| NEWPH3 | Schizophrenia | LB Pharmaceuticals Inc. | LBPEUR | PHASE3 | 2027-06 | NCT07363577 |
| NEWPH3 | Schizophrenia | Bostal Drug Delivery Co., Ltd | — | PHASE2/PHASE3 | 2027-08 | NCT07722728 |
| NEWPH3 | Schizophrenia | Bostal Drug Delivery Co., Ltd | — | PHASE2/PHASE3 | 2027-08 | NCT07742280 |
| NEWPH3 | Schizophrenia | Minerva Neurosciences | NERV | PHASE3 | 2027-12 | NCT07565428 |
ILMN — Illumina, Inc. (23 trials · 6 readouts · 13 new)
Franchises: Neuroblastoma, Parkinson Disease (PD), Lewy Body Dementia (LBD), Heart Failure
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | Parkinson Disease (PD) | Hillhurst Biopharmaceuticals, Inc. | — | PHASE2 | 2026-12-31 | NCT07005180 |
| NEWREADOUT | Parkinson Disease (PD) | GEN İlaç ve Sağlık Ürünleri A.Ş. | — | PHASE2 | 2027-03-01 | NCT07322887 |
| NEWREADOUT | Neuroblastoma | Beijing Biotech | — | PHASE1/PHASE2 | 2027-03-14 | NCT07502287 |
| READOUT | Lewy Body Dementia (LBD) | EIP Pharma Inc | EIPIX | PHASE2 | 2026-03-11 | NCT06815965 |
| READOUT | Neuroblastoma | Elicio Therapeutics | ELTX | PHASE1/PHASE2 | 2026-04-20 | NCT05726864 |
| READOUT | Neuroblastoma | USWM CT, LLC | — | PHASE1/PHASE2 | 2026-10-01 | NCT05642455 |
| RESULTS | Lewy Body Dementia (LBD) | EIP Pharma Inc | EIPIX | PHASE2 | 2020-06-30 | NCT04001517 |
| RESULTS | Lewy Body Dementia (LBD) | Eisai Inc. | ESALY | PHASE2 | 2021-12-08 | NCT04764669 |
| RESULTS | Lewy Body Dementia (LBD) | CuraSen Therapeutics, Inc. | — | PHASE2 | 2022-07-04 | NCT04739423 |
| RESULTS | Lewy Body Dementia (LBD) | LeonaBio | LONA | PHASE2 | 2023-04-19 | NCT04831281 |
| RESULTS | Lewy Body Dementia (LBD) | Cognition Therapeutics | CGTX | PHASE2 | 2024-11-25 | NCT05225415 |
| NEWPH3 | Parkinson Disease (PD) | Zhejiang Vimgreen Pharmaceuticals, Ltd. | — | PHASE2/PHASE3 | 2027-10-01 | NCT07725562 |
| NEWPH3 | Parkinson Disease (PD) | Hangzhou PhecdaMed Co., Ltd. | — | PHASE3 | 2028-01-15 | NCT07741045 |
| NEWPH3 | Lewy Body Dementia (LBD) | ACADIA Pharmaceuticals Inc. | AKR | PHASE3 | 2029-02 | NCT07095465 |
| NEWPH3 | Parkinson Disease (PD) | Annovis Bio Inc. | ANVS | PHASE2/PHASE3 | 2029-09 | NCT07284784 |
UTHR — United Therapeutics Corporation (24 trials · 4 readouts · 14 new)
Franchises: Type 2 Diabetes, Obesity & Overweight, ESRD (End-Stage Renal Disease), Kidney Transplantation
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Kidney Transplantation | iCoat Medical AB | — | PHASE2/PHASE3 | 2026-12 | NCT06582485 |
| NEWREADOUT | Kidney Transplantation | AiCuris Anti-infective Cures AG | — | PHASE2 | 2026-09-30 | NCT07503561 |
| NEWREADOUT | ESRD (End-Stage Renal Disease) | R1 Therapeutics | RCM | PHASE2 | 2027-02-28 | NCT06712654 |
| READOUTPH3 | Type 2 Diabetes | Eurofarma Laboratorios S.A. | — | PHASE3 | 2027-04-30 | NCT06560333 |
| NEWPH3 | Type 2 Diabetes | Amgen | AMGUSD | PHASE3 | 2027-12-26 | NCT07684144 |
| NEWPH3 | Type 2 Diabetes | Ascletis Pharma (China) Co., Limited | — | PHASE3 | 2028-07 | NCT07743450 |
| NEWPH3 | ESRD (End-Stage Renal Disease) | Apellis Pharmaceuticals, Inc. | APLS | PHASE3 | 2029-06 | NCT07020832 |
| NEWPH3 | Kidney Transplantation | Sanofi | SNYNF | PHASE2/PHASE3 | 2029-08-15 | NCT07412470 |
| NEWPH3 | Type 2 Diabetes | Novo Nordisk A/S | NONOF | PHASE3 | 2029-09-07 | NCT07282613 |
| NEWPH3 | Kidney Transplantation | Biogen | BIIB | PHASE3 | 2031-05-28 | NCT07444489 |
| NEW | Type 2 Diabetes | Cilcare SAS | — | PHASE1/PHASE2 | 2027-07 | NCT07472907 |
| NEW | ESRD (End-Stage Renal Disease) | Suzhou Alphamab Co., Ltd. | — | PHASE1/PHASE2 | 2027-08-15 | NCT07201467 |
| NEW | Kidney Transplantation | Biogen | BIIB | PHASE2 | 2028-02-10 | NCT07219043 |
| NEW | Kidney Transplantation | Nefro Avillion Clinical Development, LLC | — | PHASE2 | 2028-03-28 | NCT07508787 |
| NEW | Kidney Transplantation | Veloxis Pharmaceuticals | — | PHASE2 | 2028-10 | NCT07290777 |
ASND · OWNED — Ascendis Pharma A/S (61 trials · 6 readouts · 11 new)
Franchises: Achondroplasia, Hypoparathyroidism, Growth Hormone Deficiency, Pediatric, Turner Syndrome
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUTPH3 | Turner Syndrome | Rhythm Pharmaceuticals, Inc. | RHYTHMUSD | PHASE3 | 2027-03-13 | NCT06760546 |
| READOUTPH3 | Achondroplasia | QED Therapeutics, a BridgeBio company | — | PHASE3 | 2025-12-18 | NCT06164951 |
| READOUTPH3 | Turner Syndrome | Rhythm Pharmaceuticals, Inc. | RHYTHMUSD | PHASE3 | 2026-06-24 | NCT06596135 |
| RESULTSPH3 | Turner Syndrome | Eli Lilly and Company | LLY* | PHASE3 | 2007-12 | NCT00191113 |
| RESULTSPH3 | Turner Syndrome | Ipsen | IPSEY | PHASE3 | 2008-07 | NCT00234533 |
| RESULTSPH3 | Hypoparathyroidism | Shire | SHPG | PHASE3 | 2011-09-23 | NCT01268098 |
| RESULTSPH3 | Hypoparathyroidism | Shire | SHPG | PHASE3 | 2011-09-28 | NCT00732615 |
| RESULTSPH3 | Growth Hormone Deficiency, Pediatric | Pfizer | PFE | PHASE3 | 2011-10 | NCT01112865 |
| RESULTSPH3 | Hypoparathyroidism | Shire | SHPG | PHASE3 | 2012-04-26 | NCT01455181 |
| RESULTSPH3 | Growth Hormone Deficiency, Pediatric | Versartis Inc. | VSAR | PHASE3 | 2017-08-23 | NCT02339090 |
| RESULTSPH3 | Hypoparathyroidism | Shire | SHPG | PHASE3 | 2018-06-08 | NCT01297309 |
| RESULTSPH3 | Growth Hormone Deficiency, Pediatric | OPKO Health, Inc. | OPK | PHASE3 | 2019-08 | NCT02968004 |
| RESULTSPH3 | Achondroplasia | BioMarin Pharmaceutical | BMRN | PHASE3 | 2019-10-30 | NCT03197766 |
| RESULTSPH3 | Hypoparathyroidism | Shire | SHPG | PHASE3 | 2020-04-14 | NCT03364738 |
| RESULTSPH3 | Turner Syndrome | Novo Nordisk A/S | NONOF | PHASE3 | 2024-06-07 | NCT05723835 |
LLY · OWNED — Eli Lilly and Company (28 trials · 2 readouts · 12 new)
Franchises: Overweight, Obesity, Diabetes Mellitus, Type 2, Alzheimer Disease
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| READOUTPH3 | Diabetes Mellitus, Type 2 | Eurofarma Laboratorios S.A. | — | PHASE3 | 2027-04-30 | NCT06560333 |
| READOUTPH3 | Alzheimer Disease | JYAMS PET Research & Development Limited | — | PHASE3 | 2027-04-30 | NCT07752784 |
| NEWPH3 | Diabetes Mellitus, Type 2 | The United Bio-Technology (Hengqin) Co., Ltd. | — | PHASE3 | 2027-09-24 | NCT07659574 |
| NEWPH3 | Diabetes Mellitus, Type 2 | Amgen | AMGUSD | PHASE3 | 2027-12-26 | NCT07684144 |
| NEWPH3 | Diabetes Mellitus, Type 2 | The United Bio-Technology (Hengqin) Co., Ltd. | — | PHASE3 | 2028-02-29 | NCT07653477 |
| NEWPH3 | Diabetes Mellitus, Type 2 | Ascletis Pharma (China) Co., Limited | — | PHASE3 | 2028-07 | NCT07743450 |
| NEWPH3 | Alzheimer Disease | AB Science | ABSCF | PHASE3 | 2028-12 | NCT05564169 |
| NEWPH3 | Alzheimer Disease | Moleac Pte Ltd. | — | PHASE3 | 2029-02 | NCT07191028 |
| NEWPH3 | Diabetes Mellitus, Type 2 | Novo Nordisk A/S | NONOF | PHASE3 | 2029-09-07 | NCT07282613 |
| NEW | Diabetes Mellitus, Type 2 | Cilcare SAS | — | PHASE1/PHASE2 | 2027-07 | NCT07472907 |
| NEW | Alzheimer Disease | Merry Life Biomedical Co., Ltd. | — | PHASE2 | 2028-04-30 | NCT07612150 |
| NEW | Alzheimer Disease | Risen (Suzhou) Pharma Tech Co., Ltd. | — | PHASE2 | 2029-05 | NCT07579884 |
| NEW | Alzheimer Disease | Sanofi | SNYNF | PHASE2 | 2029-07-31 | NCT07688213 |
| NEW | Alzheimer Disease | CellSight Technologies, Inc. | — | PHASE2 | 2029-09-16 | NCT07611357 |
| PH3 | Diabetes Mellitus, Type 2 | Carnot Laboratories | — | PHASE3 | 2027-10 | NCT07628985 |
PTGX — Protagonist Therapeutics, Inc. (61 trials · 9 readouts · 5 new)
Franchises: Polycythemia Vera, β-thalassemia, Ineffective Erythropoiesis, Ulcerative Colitis Chronic Moderate
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| READOUTPH3 | Polycythemia Vera | PharmaEssentia Japan K.K. | — | PHASE3 | 2026-06-30 | NCT04655092 |
| READOUTPH3 | Polycythemia Vera | Italfarmaco | — | PHASE3 | 2026-07 | NCT06093672 |
| RESULTSPH3 | β-thalassemia | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2008-04 | NCT00171210 |
| RESULTSPH3 | β-thalassemia | Celgene | CELG | PHASE3 | 2021-01-05 | NCT02604433 |
| RESULTSPH3 | Polycythemia Vera | Celgene | CELG | PHASE3 | 2021-11-26 | NCT03755518 |
| RESULTSPH3 | Polycythemia Vera | Sierra Oncology LLC - a GSK company | — | PHASE3 | 2021-12-03 | NCT04173494 |
| RESULTSPH3 | β-thalassemia | Genetix Biotherapeutics Inc. | — | PHASE3 | 2022-03-31 | NCT02906202 |
| RESULTSPH3 | β-thalassemia | Genetix Biotherapeutics Inc. | — | PHASE3 | 2022-11-15 | NCT03207009 |
| RESULTSPH3 | Polycythemia Vera | Celgene | CELG | PHASE3 | 2022-12-15 | NCT03952039 |
| RESULTSPH3 | Polycythemia Vera | Incyte Corporation | INCY | PHASE3 | 2023-08-03 | NCT04551066 |
| RESULTSPH3 | Polycythemia Vera | Incyte Corporation | INCY | PHASE3 | 2023-08-16 | NCT04551053 |
| RESULTSPH3 | Polycythemia Vera | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2023-08-23 | NCT04603495 |
| RESULTSPH3 | β-thalassemia | Agios Pharmaceuticals, Inc. | AGIO | PHASE3 | 2023-11-13 | NCT04770753 |
| RESULTSPH3 | β-thalassemia | Agios Pharmaceuticals, Inc. | AGIO | PHASE3 | 2024-04-11 | NCT04770779 |
| RESULTSPH3 | Ulcerative Colitis Chronic Moderate | Eli Lilly and Company | LLY* | PHASE3 | 2024-08-09 | NCT05767021 |
LNTH · OWNED — Lantheus Holdings, Inc. (24 trials · 1 readouts · 11 new)
Franchises: Alzheimer Disease, Cardiac Disease, Coronary Artery Disease, Kawasaki Disease
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| READOUTPH3 | Alzheimer Disease | JYAMS PET Research & Development Limited | — | PHASE3 | 2027-04-30 | NCT07752784 |
| RESULTSPH3 | Kawasaki Disease | Tanabe Pharma Corporation | 9644.T | PHASE3 | 2014-10 | NCT01596335 |
| NEWPH3 | Coronary Artery Disease | EBI Anti Sepsis BV | — | PHASE3 | 2027-06-01 | NCT07357675 |
| NEWPH3 | Alzheimer Disease | AB Science | ABSCF | PHASE3 | 2028-12 | NCT05564169 |
| NEWPH3 | Alzheimer Disease | Moleac Pte Ltd. | — | PHASE3 | 2029-02 | NCT07191028 |
| NEWPH3 | Alzheimer Disease | Eli Lilly and Company | LLY* | PHASE3 | 2029-09 | NCT07602582 |
| NEW | Coronary Artery Disease | Nyrada Pty Ltd | — | PHASE2 | 2027-06-30 | NCT07362446 |
| NEW | Coronary Artery Disease | Beijing Inno Medicine Co., Ltd. | — | PHASE2 | 2027-07-31 | NCT07521007 |
| NEW | Alzheimer Disease | Merry Life Biomedical Co., Ltd. | — | PHASE2 | 2028-04-30 | NCT07612150 |
| NEW | Alzheimer Disease | Eli Lilly and Company | LLY* | PHASE2 | 2028-08 | NCT07589595 |
| NEW | Alzheimer Disease | Risen (Suzhou) Pharma Tech Co., Ltd. | — | PHASE2 | 2029-05 | NCT07579884 |
| NEW | Alzheimer Disease | Sanofi | SNYNF | PHASE2 | 2029-07-31 | NCT07688213 |
| NEW | Alzheimer Disease | CellSight Technologies, Inc. | — | PHASE2 | 2029-09-16 | NCT07611357 |
| PH3 | Kawasaki Disease | Baxalta now part of Shire | — | PHASE3 | 2003-12-16 | NCT00157079 |
| PH3 | Alzheimer Disease | Samsung Pharmaceutical Co., Ltd. | — | PHASE3 | 2028-01 | NCT05303701 |
BSX — Boston Scientific Corporation (18 trials · 1 readouts · 10 new)
Franchises: In-Stent Restenosis, Hepatocellular Carcinoma, Inoperable Hepatocellular Carcinoma
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | Hepatocellular Carcinoma | Riboscience, LLC. | — | PHASE2 | 2027-04 | NCT07175441 |
| RESULTSPH3 | Inoperable Hepatocellular Carcinoma | Pfizer | PFE | PHASE3 | 2011-12 | NCT00699374 |
| RESULTSPH3 | Inoperable Hepatocellular Carcinoma | Daiichi Sankyo | DSNKY | PHASE3 | 2017-03-28 | NCT01755767 |
| RESULTS | Inoperable Hepatocellular Carcinoma | Pfizer | PFE | PHASE2 | 2008-02 | NCT00247676 |
| RESULTS | Inoperable Hepatocellular Carcinoma | Genzyme, a Sanofi Company | — | PHASE2 | 2008-11 | NCT00508001 |
| RESULTS | Inoperable Hepatocellular Carcinoma | Basilea Pharmaceutica | BPMUF | PHASE2 | 2022-10-25 | NCT03230318 |
| NEWPH3 | Hepatocellular Carcinoma | Guangzhou Virotech Pharmaceutical Co., Ltd. | — | PHASE2/PHASE3 | 2028-12-31 | NCT07589244 |
| NEWPH3 | Hepatocellular Carcinoma | Exelixis | EXEL | PHASE3 | 2030-05-31 | NCT07620574 |
| NEWPH3 | Hepatocellular Carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | — | PHASE3 | 2031-04 | NCT07691762 |
| NEW | Hepatocellular Carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | — | PHASE2 | 2027-07 | NCT07682272 |
| NEW | Hepatocellular Carcinoma | Lepu Biopharma Co., Ltd. | 2157.HK | PHASE1/PHASE2 | 2028-04 | NCT07479485 |
| NEW | Hepatocellular Carcinoma | Zhejiang Haichang Biotech Co., Ltd. | — | PHASE2 | 2028-06-01 | NCT07494435 |
| NEW | Hepatocellular Carcinoma | Huahui Health | — | PHASE1/PHASE2 | 2028-10-30 | NCT07547553 |
| NEW | Hepatocellular Carcinoma | Arvinas Inc. | ARVN | PHASE1/PHASE2 | 2031-03-31 | NCT07749586 |
| NEW | Hepatocellular Carcinoma | VM Discovery, Inc. | — | PHASE1/PHASE2 | 2031-05 | NCT07636785 |
CRNX — Crinetics Pharmaceuticals, Inc. (69 trials · 3 readouts · 6 new)
Franchises: Acromegaly, Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia, Carcinoid Syndrome
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | Acromegaly | Alexion Pharmaceuticals, Inc. | ALXN | PHASE2 | 2026-06-24 | NCT07037420 |
| READOUTPH3 | Congenital Adrenal Hyperplasia | Immedica Pharma AB | — | PHASE3 | 2026-01-15 | NCT05299554 |
| RESULTSPH3 | Acromegaly | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2007-10 | NCT00372697 |
| RESULTSPH3 | Acromegaly | Ipsen | IPSEY | PHASE3 | 2008-10 | NCT00383708 |
| RESULTSPH3 | Acromegaly | Ipsen | IPSEY | PHASE3 | 2008-12 | NCT00447499 |
| RESULTSPH3 | Carcinoid Syndrome | INSYS Therapeutics Inc | VINSYS.NS | PHASE3 | 2010-02 | NCT00538850 |
| RESULTSPH3 | Carcinoid Syndrome | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2010-04 | NCT00412061 |
| RESULTSPH3 | Acromegaly | Ipsen | IPSEY | PHASE3 | 2012-02 | NCT00690898 |
| RESULTSPH3 | Acromegaly | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2013-01-22 | NCT01137682 |
| RESULTSPH3 | Carcinoid Syndrome | Ipsen | IPSEY | PHASE3 | 2013-05 | NCT00774930 |
| RESULTSPH3 | Acromegaly | Chiasma, Inc. | CHMA | PHASE3 | 2014-05 | NCT01412424 |
| RESULTSPH3 | Acromegaly | Novartis Pharmaceuticals | NVSEF | PHASE3 | 2016-03-11 | NCT00600886 |
| RESULTSPH3 | Carcinoid Syndrome | Lexicon Pharmaceuticals | LXRX | PHASE3 | 2016-03-21 | NCT01677910 |
| RESULTSPH3 | Carcinoid Syndrome | Lexicon Pharmaceuticals | LXRX | PHASE3 | 2016-03-29 | NCT02063659 |
| RESULTSPH3 | Acromegaly | Ipsen | IPSEY | PHASE3 | 2016-11 | NCT02493517 |
VCEL · OWNED — Vericel Corporation (24 trials · 1 readouts · 6 new)
Franchises: Articular Cartilage Defect, Chondral Defect, Dilated Cardiomyopathy, Osteochondritis Dissecans (OCD)
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| READOUTPH3 | Articular Cartilage Defect | Aesculap Biologics, LLC | — | PHASE3 | 2026-01 | NCT03219307 |
| RESULTSPH3 | Articular Cartilage Defect | Cellontech Co., Ltd. | — | PHASE3 | 2009-01 | NCT01050816 |
| RESULTSPH3 | Dilated Cardiomyopathy | Pfizer | PFE | PHASE3 | 2022-10-13 | NCT03439514 |
| RESULTS | Articular Cartilage Defect | Medipost, Inc. | 078160.KQ | PHASE1/PHASE2 | 2017-06-02 | NCT01733186 |
| RESULTS | Dilated Cardiomyopathy | Bristol-Myers Squibb | BMY | PHASE1/PHASE2 | 2019-10-24 | NCT03447990 |
| RESULTS | Dilated Cardiomyopathy | Pfizer | PFE | PHASE2 | 2020-12-21 | NCT02351856 |
| RESULTS | Dilated Cardiomyopathy | Bristol-Myers Squibb | BMY | PHASE2 | 2024-02-22 | NCT04572893 |
| RESULTS | Dilated Cardiomyopathy | Cumberland Pharmaceuticals | CPIX | PHASE2 | 2024-03-06 | NCT03340675 |
| NEWPH3 | Dilated Cardiomyopathy | Kardigan, Inc. | KARD | PHASE2/PHASE3 | 2027-09 | NCT07210723 |
| NEW | Articular Cartilage Defect | Epibone, Inc. | — | PHASE1/PHASE2 | 2027-12-31 | NCT06895889 |
| NEW | Dilated Cardiomyopathy | Heartseed Inc. | 219A.T | PHASE1/PHASE2 | 2028-01-01 | NCT07347197 |
| NEW | Dilated Cardiomyopathy | Affinia Therapeutics | — | PHASE1/PHASE2 | 2028-12 | NCT07426419 |
| NEW | Dilated Cardiomyopathy | Nuevocor Pte. Ltd. | — | PHASE1/PHASE2 | 2030-03 | NCT07606274 |
| NEW | Dilated Cardiomyopathy | Alexion Pharmaceuticals, Inc. | ALXN | PHASE1/PHASE2 | 2032-01-27 | NCT07218887 |
| PH3 | Articular Cartilage Defect | Medipost Co Ltd. | 078160.KQ | PHASE3 | 2010-12 | NCT01041001 |
EW · OWNED — Edwards Lifesciences Corporation (2 trials · 1 readouts · 1 new)
Franchises: Mitral Valve Regurgitation, Mitral Leaflet Prolapse
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| NEWREADOUT | Mitral Valve Regurgitation | GEN İlaç ve Sağlık Ürünleri A.Ş. | — | PHASE2 | 2027-03-01 | NCT07322887 |
| RESULTS | Mitral Leaflet Prolapse | Abbott Medical Devices | — | PHASE1/PHASE2 | 2006-02 | NCT00209339 |
KRYS — Krystal Biotech, Inc. (13 trials · 1 readouts · 1 new)
Franchises: Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
| Signal | Indication | Competitor | Ticker | Phase | Readout | NCT |
|---|---|---|---|---|---|---|
| READOUTPH3 | Dystrophic Epidermolysis Bullosa | Chiesi Farmaceutici S.p.A. | — | PHASE3 | 2026-03 | NCT06917690 |
| RESULTSPH3 | Dystrophic Epidermolysis Bullosa | Organogenesis | ORGO | PHASE3 | 2008-12 | NCT00587223 |
| RESULTSPH3 | Dystrophic Epidermolysis Bullosa | Scioderm, Inc. | — | PHASE3 | 2017-07-05 | NCT02384460 |
| RESULTSPH3 | Dystrophic Epidermolysis Bullosa | Scioderm, Inc. | — | PHASE3 | 2018-09-03 | NCT02670330 |
| RESULTSPH3 | Dystrophic Epidermolysis Bullosa | Castle Creek Biosciences, LLC. | — | PHASE3 | 2023-01-17 | NCT04213261 |
| RESULTS | Dystrophic Epidermolysis Bullosa | Scioderm, Inc. | — | PHASE2 | 2014-06-24 | NCT02014376 |
| RESULTS | Dystrophic Epidermolysis Bullosa | Scioderm, Inc. | — | PHASE2 | 2018-09-14 | NCT02090283 |
| RESULTS | Dystrophic Epidermolysis Bullosa | Castle Creek Biosciences, LLC. | — | PHASE1/PHASE2 | 2020-09-29 | NCT02810951 |
| RESULTS | Dystrophic Epidermolysis Bullosa | Abeona Therapeutics, Inc | ABEO | PHASE1/PHASE2 | 2022-03-09 | NCT01263379 |
| NEW | Dystrophic Epidermolysis Bullosa | Xinnate AB | — | PHASE2 | 2027-06-30 | NCT06594393 |
| PH3 | Dystrophic Epidermolysis Bullosa | Abeona Therapeutics, Inc | ABEO | PHASE3 | 2022-10-18 | NCT04227106 |
| PH3 | Dystrophic Epidermolysis Bullosa | Abeona Therapeutics, Inc | ABEO | PHASE3 | 2025-09-30 | NCT05725018 |
| PH3 | Dystrophic Epidermolysis Bullosa | Castle Creek Biosciences, LLC. | — | PHASE3 | 2027-09 | NCT06892639 |
* = competitor also on watchlist. Internal research — do not distribute.